SCHEMBL3143646

SCHEMBL3143646

Oc1ccc(C2=CCCCC2)nc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.53
CASP3 P42574 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
ATR Q13535 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ACMSD Q8TDX5 2/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
JAK3 P52333 1/20 0.36
TRPV3 Q8NET8 1/20 0.35
PSMB5 P28074 3/20 0.35
TBK1 Q9UHD2 1/20 0.34
MAP3K8 P41279 1/20 0.33
KDR P35968 1/20 0.33
FLT3 P36888 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24366369 0.79 TDP1 (0.53) TDP1CASP3SENP8SENP7SENP6
SCHEMBL31307013 0.79 TDP1 (0.53) TDP1CASP3SENP8SENP7SENP6
SCHEMBL30469661 0.79 TDP1 (0.53) TDP1CASP3SENP8SENP7SENP6
SCHEMBL18015411 0.79 TDP1 (0.53) TDP1CASP3SENP8SENP7SENP6
SCHEMBL21988063 0.79 TDP1 (0.53) TDP1CASP3SENP8SENP7SENP6
SCHEMBL13490344 0.75 TDP1 (0.56) TDP1CASP3SENP8SENP7SENP6
SCHEMBL19794419 0.74 TDP1 (0.56) TDP1CASP3SENP8SENP7SENP6
SCHEMBL188943 0.72 MEN1 (0.55) TDP1NPC1RAB9AMEN1KMT2A
SCHEMBL10068060 0.72 QDPR (0.59)
SCHEMBL20400938 0.72 SPR (0.49) TDP1CASP3SENP8SENP7SENP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137193-B1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI SA (FR) 2017-08-09 EP disclosed
US-8642603-B2 Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof SANOFI (FR) 2014-02-04 US disclosed
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2010-03-25 US disclosed
EP-2137193-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF Sanofi-Aventis (FR) 2009-12-30 EP disclosed
WO-2008112483-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF GRM2, GRM1, GRIN2C TDP1 1955/4885CASP3 4151/4885SENP8 4722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.